

Research paper

Synthesis, characterization and anticancer activity of new 2-acetyl-5-methyl thiophene and cinnamaldehyde thiosemicarbazones and their palladium(II) complexes

Eunice A. Nyawade^{a,b,*}, Nicole R.S. Sibuyi^c, Mervin Meyer^c, Roger Lalancette^d, Martin O. Onani^{a,*}

^a Organometallics and Nanomaterials, Department of Chemistry, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa

^b School of Physical Sciences, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 62, 000-00200 Nairobi, Kenya

^c Department of Science and Innovation/Mintek Nanotechnology Innovation Centre (DSI/Mintek NIC), Biolabels Node, Department of Biotechnology, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa

^d Department of Chemistry, Rutgers, The State University of New Jersey, Newark, NJ 07102, United States

ARTICLE INFO

Keywords:

Thiosemicarbazone
Thiosemicarbazide
Palladium(II) complexes
Cinnamaldehyde
Cytotoxicity
Anticancer activity

ABSTRACT

New thiosemicarbazone (TSC) ligands, AMT-C=N-TSCH (**L1**), AMT-C=N-TSC(CH₃) (**L2**), CIN-C=N-TSCH (**L3**) and CIN-C=N-TSC(CH₃) (**L4**) (AMT = 2-acetyl-5-methylthiophene, TSCH = thiosemicarbazide, TSC(CH₃) = 4-methyl-3-thiosemicarbazide, CIN = cinnamaldehyde) were synthesized by condensation reaction. The reaction of [Pd(COD)Cl₂] with the ligands **L1**, **L2** and **L4** in the ratio 1:1 yielded complexes [Pd(**L1**)Cl] (**C1**), [Pd(**L2**)Cl₂] (**C2**), and [Pd(**L4**)₂Cl₂] (**C4**) respectively (COD = 1,5-cyclooctadiene). The reaction of [Pd(COD)Cl₂] with CIN-C=N-TSCH (**L3**) in 1:2 metal to ligand ratio yielded the complex [Pd(**L3**)₂] (**C3**). The ligands and the complexes were characterized by UV-Vis, FT-IR, NMR, elemental analysis and conductivity measurements. The ligand **L1** coordinated to the metal in a tridentate fashion while **L2**, **L3** and **L4** coordinated in a bidentate fashion. The ligands **L1** and **L3** coordinated to the metal as thiol anions while ligand **L4** coordinated via the thione sulphur. Conductivity measurements of the metal complexes in dimethyl sulfoxide showed that the chloride ions complexes **C1**, **C2** and **C4** are within the coordination spheres. The crystal structures of ligands **L2** and **L4** were obtained from a Bruker Smart KAPPA APEXII DUO diffractometer with graphite monochromated Mo K α radiation (λ = 0.71073 Å). Cytotoxic activity of the compounds was investigated against the human cancer cell lines; Caco-2 (colon), HeLa (cervical), Hep-G2 (hepatocellular), MCF-7 (breast), PC-3 (prostate) and MCF-12A (non-cancer breast) cells. The complex **C2** exhibited excellent broad spectrum growth inhibition activity against all the human cell lines tested except for the non-cancer breast cells. All the metal complexes synthesized inhibited the proliferation of human prostate cancer cell.

1. Introduction

The chemistry of transition metal complexes of thiosemicarbazone (TSC) ligands has attracted a lot of research interests due to the numerous pharmacological properties portrayed by both the ligands and the complexes [1]. The excellent chelating property of TSCs has been an attractive feature in coordination chemistry hence the vast interest in their chemistry for a span of six decades [2–4]. The TSCs are a class of N, S bidentate Schiff base ligands which are generally synthesized by the condensation of a ketone or an aldehyde with a thiosemicarbazide under suitable reaction conditions.

Since TSCs can exist as thione-thiol tautomers, they can coordinate

to the metal center either in the neutral form or, an anionic form generated after loss of a proton from the thioamide nitrogen (NH) or thiol sulphur (SH). The TSC ligand coordinate to various metals in a bidentate manner via the N and S atoms or in a tridentate fashion if there is an extra donor group (D) such as O, N or S in the molecule to give metal complexes of different geometries [5,6]. Various coordination modes exhibited by the TSC ligands have been documented [7]. Pd (II) and Pt(II) complexes with TSCs derived from 2-thiophenecarboxaldehyde, 5-methyl-2-thiophene carboxaldehyde and other aldehydes and ketones exhibit various coordination modes and have been reported to be biologically active [8–12]. The presence of nitrogen and sulfur donor atoms in the ligand may be responsible for their potential

* Corresponding authors at: Organometallics and Nanomaterials, Department of Chemistry, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa.

E-mail addresses: enyawade@juat.ac.ke (E.A. Nyawade), monani@uwc.ac.za (M.O. Onani).

<https://doi.org/10.1016/j.ica.2020.120036>

Received 12 June 2020; Received in revised form 18 September 2020; Accepted 20 September 2020

Available online 24 September 2020

0020-1693/ © 2020 Elsevier B.V. All rights reserved.

biological activity.

The biological activity of TSC derivatives and their metal complexes depend on the parent aldehyde and ketone, and the central metal ion of the complexes. Heterocyclic TSCs and their Pd(II) and Pt(II) complexes exhibit a great variety of biological activities against various tumors [13,14] viruses [15,16], fungi [17], 18bacteria [15,18], protozoa [12,19,20], malaria [21], and convulsions [22].

The cinnamaldehyde (CIN), a naturally occurring phytochemical compound, possesses highly significant properties such as anti-inflammatory, oxidative and anti-oxidative making it a suitable candidate for anticancer drugs. It has been shown to exert chemopreventive activity against several types of human cancer cells by inducing apoptosis and thus regulating cancer cell invasion and metastasis [23]. CIN has found application in treating various types of cancer, including breast, prostate, colon, leukemia, liver, and oral cancers [24,25]. CIN has also been shown to reduce the spontaneous mutant frequency in *Salmonella typhimurium* strain TA104 and *Escherichia coli* by 50% [26,27]. Owing to the potential of CIN and derivatives as therapeutic agents, researches on chemical syntheses and modifications have been carried out to gain chemical entities with more potent bioactivity and favorable druggability [28,29].

It is worth noting that coordination of ligands to metals give them a three dimensional orientation which aid their specific molecule recognition thus improving their biological activity [30,31].

The fact that TSCs are good chelating ligands with great pharmacological activities and that their coordination to the Pd metal center may trigger or enhance their biological activity, greatly inspired this study. New TSCs based thiophene derivative (a heterocyclic ketone) and CIN, coordinated to Pd(II) ion, were prepared and their mode of coordination and anticancer activities determined. We therefore herein report for the first time the synthesis and cytotoxicity studies of Pd(II) complexes of 2-acetyl-5-methyl thiophene TSCs and CIN TSCs.

2. Materials and methods

2.1. General methods and materials

All reactions herein were performed under inert conditions using Schlenk techniques and monitored by thin layer chromatography using Merck silica gel 60 F₂₅₄ plates. 2-Acetyl-5-methylthiophene (AMT), CIN, TSC-H and 4-methyl-3-thiosemicarbazide (TSC-CH₃) were purchased from Sigma Aldrich and used without further purification. The organic solvents; ethanol, methanol, methylene chloride, diethyl ether were obtained from Sigma Aldrich and purified by standard techniques. Melting points were determined using a Stuart Scientific SMP 10 apparatus. Solid state Fourier Transform infrared (FT-IR) on potassium bromide (KBr) were recorded on a Perkin Elmer Spectrum Two model FT-IR Spectrophotometer (4000–400 cm⁻¹). ¹H and ¹³C NMR of the compounds in deuterated dimethylsulfoxide (DMSO-*d*₆) using trimethyl silane as an internal standard was recorded at 25 °C on a Bruker Avance III HD Nanobay 400 MHz NMR spectrometer equipped with a 5 mm BBO probe. Electronic spectra were recorded on a Thermo Scientific Nicolet Evolution 100 Ultraviolet visible (UV-Vis) Spectrophotometer. Elemental analyses were performed on a LECO CNHS-932 micro-analyzer at the Central Analytical Facilities, Stellenbosch University, South Africa. Conductivity measurements were performed on a HANNA EC 215 conductivity meter. The single crystal structures of **L2** and **L4** were obtained from a Bruker Smart KAPPA APEXII DUO diffractometer with graphite monochromated Mo K α radiation (λ = 0.71073 Å) at Rutgers, the State University of New Jersey, Newark, USA. The metal precursor [Pd(COD)Cl₂] (COD = 1,5-cyclooctadiene) was prepared following previously reported methods [32,33].

2.2. Syntheses

2.2.1. Synthesis of 2-acetyl-5-methylthiophene TSCs ligands **L1** and **L2** (2E)-2-[1-(5-Methyl-2-thienyl)ethylidene]hydrazinecarbothioamide (AMT-C=N-TSCH), **L1**

TSC-H, (1.0 mmol; 91.13 mg) was dissolved in 10 mL methanol in a Schlenk tube and stirred under reflux for 30 min. To the methanolic solution of TSC-H, a solution of AMT (0.0 mmol; 140.2 mg) in prepared in 10 mL methanol was added drop wise while stirring continuously. Two drops of H₂SO₄ was added to the mixture and stirred under reflux for 2 hr. The solution turned pale yellow. A whitish cream precipitate appeared on cooling. The mixture was filtered by use of a cannula and the residue was washed with cold methanol. The residue was dried under reduced pressure for 3 h and characterized by FTIR, NMR, UV-vis and elemental analysis. The yield was 67.0% (142.92 mg) and melting point was found to be 172–174 °C.

Analysis:

Molecular formula: C₈H₁₁N₃S₂. Elemental analysis: Calculated: C; 45.04, H; 5.20, N; 19.70, S; 30.06%. Found: C; 45.30, H; 5.30, N; 20.16, S; 30.32%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.42 (s, 3H), δ 2.27 (s, 3H), δ 6.78 (m, *J* = 1.48 Hz, 1H(thiophene)), δ 7.31 (d, *J* = 3.62 Hz, 1H(thiophene)), δ 8.28 (s, 1H (–NH)). δ 10.39(s, 1H (NNH)). ¹³C NMR (400 MHz, DMSO-*d*₆): δ 178.9 (C=S), δ 145.5 (C=N), δ 142.9 (C–S), δ 140.9 (C–S), δ 128.8 (C=C), δ 126.8 (C=C), δ 15.8 (CH₃), δ 14.8 (CH₃). IR (KBr, solid state; cm⁻¹): ν (H–N–H) 3366, 3263, ν (NN–H) 3119, ν (C–N) 1629, 1521, ν (C=S) 1286, ν (C–S)thiophene 796 ν (–N–N) 993. UV-Vis (DMSO), λ_{max} , nm (ϵ , M⁻¹cm⁻¹) 341 (1030).

(2E)-N-Methyl-2-[1-(5-Methyl-2-thienyl)ethylidene]hydrazinecarbothioamide (AMT-C=N-TSC(CH₃)), **L2**

The same procedure described for the synthesis of ligand **L1** was followed in the preparation of ligand **L2**. Solutions of TSC-CH₃ (1.0 mmol, 105.2 mg) and AMT (1.0 mmol, 140.2 mg) in 10 mL methanol were used. A whitish cream solid obtained in 71% yield was characterized by elemental analysis, FTIR, NMR and UV-vis. It melted at a temperature of 176 °C. Crystals of ligand **L2** were grown by dissolving the whitish cream solid in ethanol followed by addition of a layer of diethyl ether onto the solution. The solution was left undisturbed for 48 h. Whitish cream needle shaped crystals of ligand **L2** were obtained.

Analysis:

Molecular formula: C₉H₁₃N₃S₂. Elemental analysis: Calculated: C; 47.55, H; 5.76, N; 18.48, S; 28.21%. Found: C; 47.70, H; 5.70, N; 18.01, S; 27.88%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.26 (s, 3H, CH₃), δ 2.43 (s, 3H, CH₃), δ 3.02 (s, *J* = 4.62, 3H, NCH₃), δ 6.78(q, *J* = 1.50 Hz, 1H(thiophene)), δ 7.30 (d, *J* = 3.61 Hz, 1H(thiophene)), δ 7.97 (d, *J* = 4.35 Hz, 1H (–NH)). δ 10.25(s, 1H (NNH)). ¹³C NMR (400 MHz, DMSO-*d*₆): δ 178.8 (C=S), δ 145.3 (C=N), δ 142.7 (C–S), δ 140.9 (C–S), δ 128.5 (C=C), δ 126.5 (C=C), δ 31.5 (CH₃), δ 15.7 (CH₃), δ 14.8 (CH₃). IR (KBr, solid state; cm⁻¹): ν (–N–H) 3331, ν (NN–H)3246, ν (H₂C–H) 2924, ν (–C=N) 1541, 1506, ν (C=S) 1236, ν (–N–N) 1042, ν (C–S)thiophene658. UV-Vis (DMSO), λ_{max} , nm (ϵ , M⁻¹cm⁻¹) 342 (1000).

2.2.2. Synthesis of CIN TSCs, **L3** and **L4**

(2E)-2-[(2E)-3-Phenyl-2-propen-1-ylidene]hydrazinecarbothioamide (CIN-C=N-TSCH), **L3**

TSC-H (1.0 mmol, 91.13 mg) in 10 mL dry methanol was added in a clean Schlenk tube and stirred under reflux for 30 min. 10 mL methanolic solution of CIN (1.0 mmol, 0.13 mL) was slowly added to the solution followed by a drop of conc. H₂SO₄. The mixture was stirred under reflux for 2 h after which it was allowed to cool to room temperature. A pale yellow precipitate formed, mixture was filtered via a cannula, washed with cold methanol and dried under reduced pressure for 3 h. The solid obtained in 70% yield melted at a temperature of 121.0 °C.

Analysis:

Molecular formula: $C_{10}H_{11}N_3S$. Elemental analysis: Calculated: C; 58.51, H; 5.40, N; 20.47, S; 15.62%. Found: C; 58.40, H; 5.81, N; 19.98, S; 15.27%. 1H NMR (400 MHz, DMSO, d_6): δ 11.4 (s, 1H (NNH)), δ 8.19 (s, 1H (–NH)), δ 7.90 (d, J = 9.21 Hz, 1H (N = CH)), δ 7.62 (s, 1H (–NH)), δ 7.56 (d, J = 7.28 Hz, 2H(phenyl)), δ 7.37, (m, J = 8.50 Hz, 3H(phenyl)), δ 7.0 (d, J = 16.14 Hz, 1H(allyl)), δ 6.88, (dd, J = 8.06 Hz, 1H(allyl)). ^{13}C NMR (400 MHz, CD_3OD): δ 178.1 (C=S), δ 145.2 (C=N), δ 136.3, 129.4, 129.3, 127.4, (C(Phenyl)), 139.3, 125.5 (C=C(allyl)). IR (KBr, solid state; cm^{-1}): ν (H–N–H) 3415, 3254, ν (NN–H), 3147, ν (phenyl–C–H) 3000, ν (C=N) 1588, 1521, ν (C=S) 1277, ν (N–N) 1085. UV–Vis (DMSO), λ_{max} , nm (ϵ , $M^{-1}cm^{-1}$) 345 (1470), 258sh (1248).

(2E)-N-Methyl-2-[(2E)-3-Phenyl-2-propen-1-ylidene]hydrazinecarbothioamide $CIN-C=N-TSC(CH_3)$, **L4**

The same procedure described for the ligand **L3** was followed in the preparation of ligand **L4**. Solutions of AMT (1.0 mmol, 105.2 mg) and CIN (1.0 mmol, 0.13 mL) in 10 mL methanol were used. A yellow powder obtained in 68% yield was characterized by elemental analysis, FTIR, NMR and UV–vis. It melted at a temperature of 168–170 °C. Crystals suitable for single crystal x-ray diffraction was obtained by following the procedure described for crystal growth in Section 2.2.1. Pale yellow needle-shaped crystals were obtained.

Analysis:

Molecular formula: $C_{11}H_{13}N_3S$. Elemental analysis: Calculated: C; 60.24, H; 5.97, N; 19.16, S; 14.64%. Found: C; 60.41, H; 5.97, N; 19.01, S; 14.69%. 1H NMR (400 MHz, DMSO- d_6): δ 11.46 (s, 1H (NNH)), δ 8.30 (d, J = 4.49 Hz, 1H (–NH)), δ 7.91 (d, J = 9.20, 1H (N = CH)), δ 7.55 (d, J = 7.33 Hz, 2H(phenyl)), δ 7.37, (m, J = 35 Hz, 3H(phenyl)), δ 7.0 (d, J = 16.13 Hz, 1H(allyl)), δ 6.87 (dd, J = 8.44 Hz, 1H(allyl)), δ 2.98 (d, J = 4.55 Hz, 3H (CH₃)). ^{13}C NMR (400 MHz, DMSO- d_6): δ 177.9 (C=S), δ 144.7 (C=N), δ 136.6, 129.4, 129.3, 127.3, (C(Phenyl)), 139.1, 125.5 (C=C(allyl)), 31.3 (N–CH₃). IR (KBr, solid state; cm^{-1}): ν (N–H) 3353, ν (NN–H) 3164, ν (phenyl–C–H) 2991, ν (C=N) 1532, ν (C=S) 1256, 748, ν (N–N) 1084. UV–Vis (DMSO), λ_{max} , nm (ϵ , $M^{-1}cm^{-1}$) 344 (1487), 361sh (1163).

2.2.3. Synthesis of the Pd(II) complexes

The TSC ligand was generally dissolved in methanol in a Schlenk tube and stirred for 10 min at room temperature. A solution of Pd (COD)Cl₂ in methylene chloride was added to the contents of the Schlenk tube drop wise as the mixture was continuously stirred. An orange colored precipitate appeared almost immediately. The mixture was stirred at room temperature for 4 h and the solid was allowed to settle at the bottom of the Schlenk tube. The mixture was filtered; the residue was washed with cold methanol, rinsed with diethyl ether and dried under reduced pressure. The products were characterized by FTIR, UV–vis, 1H NMR, melting point and elemental analysis.

2.2.3.1. Synthesis of complex C1, Pd(L1)Cl. The ligand **L1** (0.5 mmol, 106.66 mg) was dissolved in methanol in a Schlenk tube at room temperature and stirred. An equimolar amount of Pd(COD)Cl₂ solution in methylene chloride was added to the Schlenk tube. The rest of the procedure as described in Section 2.2.3 was followed. A dark orange precipitate was formed in 83% yield. The solid decomposes at 248 °C.

Analysis:

Molecular formula: $C_8H_{10}ClN_3PdS_2$. Elemental analysis: Calculated: C; 27.13, H; 2.85, N; 11.86, S; 18.10%. Found: C; 27.02, H; 2.50, N; 11.69, S; 18.01%. 1H NMR (400 MHz, DMSO- d_6): δ 2.36 (s, 3H (CH₃)), δ 2.45 (s, 3H, (CH₃ thiophene)), δ 6.87 (d, J = 3.92 Hz, 1H(thiophene)), δ 7.4554 (d, J = 3.96 Hz, 1H (thiophene)), δ 9.23 (s, 2H (NH₂)). IR (KBr, solid state; cm^{-1}): ν (H–N–H) 3342, ν (C=N) 1624, 1530, (N–N) 1046, ν (C–S)thiophene 646, ν (Pd–N) 551, ν (Pd–S) 406, 478. UV–Vis (DMSO), λ_{max} , nm (ϵ , $M^{-1}cm^{-1}$) 291 (1589), 342 (1166), 393sh (433), 480sh (218).

2.2.3.2. Synthesis of complex C2, Pd(L2)Cl₂. The ligand AMT–C=

N–TSC–CH₃ (0.1 mmol, 22.73 mg) and an equimolar amount of the precursor were used as per the procedure described in Section 2.2.3.1 to give an orange solid that turns black and melts at 217 °C in 89% yield.

Molecular formula: $C_9H_{12}Cl_2N_3PdS_2$. Elemental analysis: Calculated: C; 26.71, H; 3.24, N; 10.38, S; 15.85%. Found: C; 26.65, H; 3.48, N; 10.36, S; 15.81%. 1H NMR (400 MHz, DMSO- d_6): δ 2.46 (s, 3H), δ 2.58 (s, 3H (thiophene)), δ 2.94 (s, 3H (NCH₃)), δ 6.8762 (d, J = 3.36 Hz, 1H(thiophene)), δ 7.49 (d, J = 3.91 Hz, 1H (thiophene)), δ 8.72 (s, 1H (–NH)), δ 10.26 (s, 1H (NNH)). IR (KBr, solid state; cm^{-1}): ν (N–H) 3273, ν (NN–H) 3181, ν (H₂C–H) 3004, 2932, ν (C=N) 1565, 1514, ν (C=C–) 1441, 1397, ν (C=S) 1229, ν (N–N) 1048, ν (C–S)thiophene 536, ν (Pd–N) 530, ν (Pd–S) 450, 497. UV–Vis (DMSO), λ_{max} , nm (ϵ , $M^{-1}cm^{-1}$) 340 (1472), 393sh (417), 486 (87.2).

2.2.3.3. Synthesis of complex C3, Pd(L3)₂. To a methanolic solution of ligand **L3** (1.0 mmol, 205.28 mg) in a Schlenk tube, a solution of Pd (COD)Cl₂ (0.5 mmol, 142.76 mg) in methylene chloride was added and the rest of the procedure followed as described in Section 2.2.3. An orange solid was obtained in 87% yield. The solid decomposes at a temperature above 281 °C.

Analysis:

Molecular formula: $C_{20}H_{20}N_6PdS_2$. Elemental analysis: Calculated: C; 46.65, H; 3.91, N; 16.32, S; 12.45%. Found: C; 46.39, H; 4.09, N; 16.11, S; 12.29%. 1H NMR (400 MHz, DMSO- d_6): δ 9.14 (2H, NH₂), δ 8.08 (m, J = 5.42 Hz, 1H (CH, allyl)), 7.62 (s, 1H (–CH, allyl)), δ 7.73 (m, J = 16.10 Hz, 5H(phenyl)). IR (KBr, solid state; cm^{-1}): ν (H–N–H) 3421, 3259, ν (phenyl–C–H) 2975, 2828, ν (C=N) 1583, 1513, ν (aromatic –C=C) 1481, ν (N–N) 977, ν (Pd–N) 508, ν (Pd–S) 475. UV–Vis (DMSO), λ_{max} , nm (ϵ , $M^{-1}cm^{-1}$) 303 (1770), 362 (1920), 417 (1412), 486 (97).

2.2.3.4. Synthesis of complex C4, Pd(L4)Cl₂. The ligand **L4** (1.0 mmol, 219.31 mg) and Pd(COD)Cl₂ (1.0 mmol, 285.51 mg) were used and the procedure described in Section 2.2.3.3 followed to give an orange solid in 81% yield. Solid turns black and decomposes above 235 °C.

Analysis:

Molecular formula: $C_{11}H_{13}Cl_2N_3PdS$. Elemental analysis: Calculated: C; 33.31, H; 3.30, N; 10.59, S; 8.08%. Found: C; 33.21, H; 3.44, N; 10.52, S; 8.07%. 1H NMR (400 MHz, DMSO, d_6): δ 11.10 (1H (NNH)), δ 8.08 (d, J = 9.61 Hz, 1H (N=CH)), δ 7.62 (m, J = 4.88 Hz, 1H (–NH)), δ 7.63–7.39 (m, 5H (phenyl)), δ 7.32 (d, J = 7.53 Hz, 1H (allyl)), δ 7.28 (dd, J = 8.44 Hz, 1H(allyl)), δ 2.83 (d, J = 8.78 Hz, 3H (CH₃)). IR (KBr, solid state; cm^{-1}): ν (N–H) 3246, ν (phenyl–C–H) 3010, 2932, ν (C=N) 1607, 1527 ν (aromatic –C=C) 1445, ν (C=S) 1165, ν (N–N) [1018], ν (Pd–N) 501, ν (Pd–S) 458. UV–Vis (DMSO), λ_{max} , nm (ϵ , $M^{-1}cm^{-1}$) 297 (1271), 370 (1690), 388 (1681), 470 (96.6).

2.3. Crystal data determination and structure refinement ligands L2 and L4

Crystals fit for single crystal X-ray diffraction studies were grown by layering solutions of the compounds in dry ethanol with a three times excess volume of diethyl ether and allowing it to stand for 48 h. **L2** and **L4** crystals were selected, glued onto the tip of glass fibers, mounted in a stream of cold nitrogen at 100(1) K and centered in the X-ray beam by using a video camera. Reflections were successfully indexed by an automated indexing routine built in the APEXII program suite [34]. The structures were solved by direct methods using SHELXS [35] and refined [34]. All structures were checked for solvent-accessible cavities using PLATON [36] and the graphics were performed with the DIAMOND [37] visual crystal structure information system software. The absorption correction was based on fitting a function to the empirical transmission surface as sampled by multiple equivalent measurements [34]. The CIF files for the crystals can be obtained from the Cambridge Crystallographic Data Centre (Supplementary Material file). The crystal data and structure refinement for the ligands **L2** and **L4** are summarized

Table 1
Crystal data and structure refinement for Ligands **L2** and **L4**.

	L2		L4	
Empirical formula	C ₉ H ₁₃ N ₃ S ₂		C ₁₁ H ₁₃ N ₃ S	
Formula weight	227.3		219.30	
Temperature	100 K		100 K	
Wavelength	1.54178 Å		1.54178 Å	
Crystal system	Monoclinic		Monoclinic	
Space group	P 21/c		P 21/n	
Unit cell dimensions (Å, °)	a = 5.5173(4) b = 11.1578(8) c = 18.0817(3)	α = 90 β = 96.00(2) γ = 90	a = 5.4418(2) b = 9.2819(3) c = 22.4502(7)	α = 90 β = 92.056(2) γ = 90
Volume	1106.98(14) Å ³		1133.27(7) Å ³	
Z	4		4	
Density (calculated)	1.364 Mg/m ³		1.285 Mg/m ³	
Absorption coefficient	4.075 mm ⁻¹		2.290 mm ⁻¹	
F(000)	483.62		466.41	
h,klmax	6, 13, 21		6, 11, 22	
Nref (reported)	1954		2004	
Data completeness	0.970		0.960	
Theta max	68.116		68.545	
Absorption correction	Numerical		Numerical	
Max. and min. transmission	0.799 and 0.544		0.843 and 0.396	
R(reflections)	0.0267 (1809)		0.0331 (1892)	
wR2(reflections)	0.0691 (1954)		0.0814 (2004)	
S	1.045		1.099	
Npar	136		138	

in Table 1.

2.4. Anticancer activity

Cytotoxicity of the compounds was tested against human cell lines obtained from American Type Culture Collection (Manassas, United States of America): Caco-2 (colon), HeLa (cervical), Hep-G2 (hepatocellular), MCF-7 (breast), PC-3 (prostate) cancers and MCF-12A (non-cancer breast) cells. The cells were cultured in their respective media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin cocktail (100 µg/mL penicillin and 100 µg/mL streptomycin). Caco-2, HeLa, HepG2, and MCF-7 cells were grown in Dulbecco's Modified Eagle Medium (DMEM); MCF-12A in DMEM-F12 containing insulin, EGF and hydrocortisone; while PC-3 cells were cultured in RPMI-1640 media. The cells were grown at 37 °C in a 5% CO₂ humidified incubator (Labotech, South Africa). The cells were seeded at 1 × 10⁵ cells/mL density in a 96-well plate and incubated at 37 °C for 24 h. The cells were treated with varying concentrations of compounds (0–100 µg/mL) and incubated at 37 °C for 24 h. Cytotoxicity of the compounds was assessed by MTT assay, a colorimetric assay that measures the reduction of yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate dehydrogenase, following manufacturer's instructions. After treatment, 10 µL of 5 mg/mL MTT (Sigma, USA) was added to each well (100 µL/well) and incubated at 37 °C for 3 h. The insoluble formazan crystals were solubilized by adding 100 µL of

DMSO. The reduction of MTT was read at 570 nm using POLARStar Omega plate reader. Cell viability was calculated using this formula:

$$\% \text{ Cell Viability} = \left(\frac{\text{Average absorbances of treated cells}}{\text{Average absorbances of control}} \right) \times 100 \%$$

The concentration of the compounds that inhibited 50% cell proliferation (IC₅₀) on each cell line was estimated using GraphPad Prism software version 5 (GraphPad Software, California, USA).

3. Results and discussion

3.1. Synthesis and characterization of the ligands

The reactions of 2-acetyl-5-methylthiophene with thiosemicarbazide and 4-methyl-3-thiosemicarbazide in methanol under reflux formed the 2-acetyl-5-methylthiophene TSC ligands **L1** and **L2** as whitish cream solids, respectively. The CIN TSC ligands **L3** and **L4** were obtained by the reaction of cinnamaldehyde with thiosemicarbazide and 4-methyl-3-thiosemicarbazide, respectively, in methanol as a solvent under reflux respectively (Fig. 1). The TSC ligands were characterized by FTIR, UV-Vis, ¹H and ¹³C NMR and elemental analysis.

3.1.1. ¹H NMR and FTIR analysis

The IR spectra of the ligands **L1** to **L4** displayed stretching frequency bands for the ν(C=N) and ν(C=S) in the regions 1584–1521 and 1256–1225 cm⁻¹, respectively. The absence of bands in the




Fig. 1. General reaction scheme for the synthesis of ligands **L1**, **L2**, **L3** and **L4**.




Fig. 2. Ligand **L2** in asymmetric unit, showing the atom-numbering scheme. Displacement ellipsoids are drawn at the 50% probability level.

carbonyl stretching frequency $\nu(\text{C}=\text{O})$ in the region $1690\text{--}1650\text{ cm}^{-1}$ and appearance of the imine stretching frequencies in the IR spectra of the ligands indicated that the imine bond was actually formed by condensation. The ^1H NMR spectra of TSCs **L3** and **L4** exhibited a signal associated with the imine proton $\text{C}=\text{NH}$ at 7.9 ppm, approximately 1.77 ppm upfield compared to the absent carbonyl proton $\text{HC}=\text{O}$ signal of the cinnamaldehyde (9.69 ppm), a confirmation that the imine bond was actually formed. The elemental analyses data further confirmed the chemical composition of the TSC. Since thiosemicarbazones have the thioamine functional group $-\text{NH}-\text{C}(\text{S})$, they are capable of exhibiting the thione-thiol tautomeric forms. They can therefore exist as thiols or thiones or a mixture of both [38]. The absence of absorption bands associated with the $-\text{S}-\text{H}$ vibration in the region $2600\text{--}2500\text{ cm}^{-1}$ confirmed that the thione form of the synthesized TSCs is predominant in the solid state [39,40]. This is further confirmed by the single crystal XRD structures of **L2** and **L4** (Figs. 2 and 3). The ^1H NMR in $\text{DMSO}-d_6$ of TSCs **L1** and **L2** exhibited a proton signal at 10.32 and 10.24 ppm respectively while **L3** and **L4** exhibited a proton signal at 11.40 and 11.42 ppm respectively; the proton signals are attributed to the $\text{N}-\text{NH}$ proton. A proton signal at 4.00 ppm attributable to the $-\text{SH}$ proton was absent [8], a clear indication that the TSCs existed as the thione tautomer even in the presence of a solvent as polar as DMSO [8]. TSCs can also exist in *Z* and *E*-isomeric forms or as a mixture of both isomers in solution. The ^1H NMR signals observed in the 10.24–11.42 ppm range are attributed to the hydrazine $\text{N}-\text{NH}$ protons falls within the literature range of 9.00–12.00 ppm reported for the *E*-isomer [8]. The absence of proton signals in the range of 14.00–15.00 ppm, normally associated with the hydrazine $\text{N}-\text{NH}$ protons in the *Z*-isomer, further confirmed that the TSC ligands existed as *E*-isomers in the DMSO solution [8]. ^{13}C




Fig. 4. Crystal structure of **L4** with displacement ellipsoids drawn at the 50% probability level.

carbon signals observed in the range 177.9–178.9 ppm and 44.5–142.5 ppm attributed to the thione $\text{C}=\text{S}$ and imine $\text{C}=\text{N}$ carbon atoms respectively further confirms the formation and existence of the TSCs in the thione tautomer. The NMR and FT-IR results therefore suggest that the thiosemicarbazone ligands exist as *E* form of the thione. It is worth noting that the crystal structure of the ligands reveal the existence of the ligands in the *E*-isomers (Figs. 2 and 4).

3.1.2. Crystal structures of ligands **L2** and **L4**

A few selected geometric parameters for the crystal structures of **L2** and **L4** are summarized in Table 2.

The ligand **L2** crystallizes as whitish cream needle shaped crystals with four molecules in the asymmetric unit. The crystal structure of the ligand **L2** is represented in Fig. 2. The crystal belongs to monoclinic crystal class and space group $P 2_1/c$. The crystal data is given in Table 1. The bond lengths and bond angles (Table 2) of the four molecules in a unit cell are equal and are in agreement with values reported for analogous molecules, 1-(Thiophen-2-yl)ethanone TSC [41–43]. The TSC fragment is close to being planar with the maximum deviation from planarity being $0.0435\text{ \AA}$ for atom C(1). The maximum deviation from planarity for the thiophene fragment is $0.045\text{ \AA}$ at atom C(5). The thiophene fragment's torsion angles are $\text{S}(2)-\text{C}(6)-\text{C}(5)-\text{C}(4) = 0.9(2)^\circ$ and $\text{S}(2)-\text{C}(3)-\text{C}(4)-\text{C}(5) = -0.0(2)^\circ$ further confirms planarity of the thiophene ring. The torsion angles $177.3(1)^\circ$ and $168.8(1)^\circ$ for $\text{N}(2)-\text{N}(1)-\text{C}(2)-\text{C}(3)$ and $\text{S}(1)-\text{C}(1)-\text{N}(2)-\text{N}(1)$ respectively, suggests that the TSC fragment has an extended conformation which may allow for intramolecular $\text{N}(3)-\text{H}(3) \cdots \text{N}(1)$ hydrogen bond formation, and generation of a 5-member ring motif. However the crystal packing does not display the anticipated $\text{N}(3)-\text{H}(3) \cdots \text{N}(1)$ intramolecular hydrogen bonds. The molecules are held together by a network of interactions which include hydrogen bonds $\text{S}(1) \cdots \text{H}(8\text{A})-\text{C}(8)$, $\text{S}(1) \cdots \text{H}(3)-\text{N}(3)$ and $\text{N}(3) \cdots \text{H}(8\text{A})-\text{C}(8)$;




Fig. 3. Crystal packing diagram of **L2** as viewed along the crystallographic *a*-axis. Intermolecular interactions are indicated by dashed lines.

Table 2
Geometric parameters of ligands **L2** and **L4**.

Bond distance in Angstroms (Å)			
L2	L4		
C(2)–N(1)	1.292(2)	C(3)–N(3)	1.290(2)
N(1)–N(2)	1.376(2)	N(3)–N(2)	1.376(2)
N(2)–C(1)	1.361(2)	N(2)–C(1)	1.355(2)
C(1)–S(1)	1.686(2)	C(1)–S(1)	1.695(2)
C(1)–N(3)	1.330(2)	C(1)–N(1)	1.324(2)
N(3)–C(9)	1.443(2)	N(1)–C(2)	1.453(2)
Bond angles in degrees (°)			
L2	L4		
C(2)–N(1)–N(2)	118.3(1)	C(3)–N(3)–N(2)	115.8(1)
N(1)–N(2)–C(1)	118.2(1)	N(3)–N(2)–C(1)	118.8(1)
C(1)–N(3)–C(9)	124.5(1)	C(1)–N(1)–C(2)	124.7(1)
N(2)–C(1)–N(3)	115.8(1)	N(2)–C(1)–N(1)	116.4(1)
N(2)–C(1)–S(1)	120.2(1)	N(1)–C(1)–S(1)	124.2(1)
N(3)–C(1)–S(1)	123.9(1)	N(2)–C(1)–S(1)	119.5(1)
Torsion angles in degrees (°)			
Ligand L2	L4		
C(2)–N(1)–N(2)–C(1)	−179.9(1)	C(3)–N(3)–N(2)–C(1)	177.7(1)
N(1)–N(2)–C(1)–S(1)	168.8(1)	N(3)–N(2)–C(1)–S(1)	176.8(1)
N(1)–N(2)–C(1)–N(3)	−10.1(2)	N(3)–N(2)–C(1)–N(1)	−4.6(2)
N(2)–C(1)–N(3)–C(9)	−1.3(2)	N(2)–C(1)–N(1)–C(2)	180.0(2)
S(2)–C(6)–C(5)–C(4)	0.9(2)		
S(2)–C(3)–C(4)–C(5)	−0.0(2)		
N(2)–N(1)–C(2)–C(3)	177.3(1)		

π -hydrogen interactions C(5) H(9A)–C(9), and C(1) H(5A)–C(5); and Van de Waals forces C(8) S(1), C(9) (9) thereby forming a three dimensional lattice structure (Fig. 3). Two adjacent molecules in the crystal lattice are joined together by S(1) H(2)–N(2) hydrogen bonds forming inversion dimmers. The C(1)–N(2) bond distance, 1.361 Å, is longer than the C(2)–N(1) bond distance, 1.282 Å; a clear indication that an imine bond exists in ligand **L2**.

The ligand **L4** formed needle shaped monoclinic crystals in P 21/n space group with four molecules in a unit cell. Fig. 4 gives an illustration of the crystal structure.

The benzene ring is planar with a slight variation in the torsion angles ranging from -0.14° to -0.84° . The TSC fragment is fairly planar with torsion angles of $177.7(1)^\circ$ and $-4.6(2)^\circ$ for C(3)–N(3)–N(2)–C(1) and N(3)–N(2)–C(1)–N(1) respectively. The benzene ring is trans-related to the thiosemicarbazone fragment about C(3) = C(4) double bond. The bond distances and bond angles are generally the same as those reported in literature [44]. Bond angles, torsion angles and bond distances for ligands **L2** and **L4** are summarized in Table 2. Intermolecular interactions S(1) N(2) and S(1) H(2)–N(2) between two adjacent molecules related to each other by inversion lead to formation of centrosymmetric dimmers. The crystal lattice is held together by a network of interactions shown in Fig. 5.

3.2. Synthesis and characterization of the Pd(II) complexes

The Pd(II) complexes were synthesized by the reaction of the TSC ligands with [Pd(COD)Cl₂] in the ratio of 1:1 for complexes **C1**, **C2** and **C4**, and a ratio of 2:1 for complex **C3** at room temperature (Scheme 1). The complexes were obtained as orange, air and moisture stable solids generally soluble in DMSO and DMF but insoluble in ethanol, methanol and water. Complexes **C1** and **C2** are soluble in methylene chloride and chloroform while complexes **C3** and **C4** are not. The new thiosemicarbazone Pd(II) complexes were characterized by elemental analysis, FTIR, UV–Vis and ¹H NMR spectroscopy.

3.2.1. IR spectroscopic studies

The infrared spectroscopic data for the imine $\nu(\text{C}=\text{N})$ and thioamide $\nu(\text{C}=\text{S})$ vibrations provides very crucial information in determining the coordination mode of the ligand (Table 3). The bands





Fig. 5. Crystal packing diagram of **L4** as viewed along the crystallographic *a*-axis. Intermolecular interactions are indicated by dashed lines.

associated with the thioamide vibrations and imine vibrations are generally expected to shift to lower frequencies signaling coordination of the ligand to the metal via the sulphur atom and the imine nitrogen atoms respectively. The shift of spectral bands on chelation of the ligands to the metal through the imine and thioamide linkages reduces the electron density on the pi-bonds, decreases the pi-character and the bond is weakened. In this study, it was observed that the bands in the region $1680\text{--}1500\text{ cm}^{-1}$ associated with imine vibrations are generally split and could be overlapping with the $\nu(\text{N}=\text{H})$ asymmetric stretches, for complexes **C1** and **C3**, and, the thiophene/benzene aromatic $\nu(\text{C}=\text{C})$ stretch. These overlaps camouflaged the expected shift to lower energy of the band due to the imine bond $\nu(\text{C}=\text{N})$ vibration and hence may not be very obvious in the spectra. Despite this observation, the bands associated with imine vibrations are generally shifted to lower frequencies in the spectra of the complexes as compared to the free ligand (Table 3). The thioamide $\nu(\text{C}=\text{S})$ bond vibration in complex **C4** observed at 1164 cm^{-1} , a lower frequency than that observed for the free ligand, an indication of coordination via the thioamide sulphur atom. The $\nu(\text{C}=\text{S})$ vibrations were absent in complexes **C1** and **C3**, a sign that the ligands coordinated to the metal in their anionic form through the sulphide, S^{2-} . A very slight shift (7 cm^{-1}) was observed in the $\nu(\text{C}=\text{S})$ vibrations for complex **C2** as compared to ligand **L2**, probably due to non-involvement of the $\text{C}=\text{S}$ bond in coordination. The coordination of the TSC ligands through the sulphur and nitrogen atoms was further confirmed by the presence of two new bands at $406\text{--}458\text{ cm}^{-1}$ and $478\text{--}508\text{ cm}^{-1}$ regions due to $\nu(\text{Pd}=\text{N})$ and $\nu(\text{Pd}=\text{S})$ vibrations respectively. It's worth noting that the $\nu(\text{N}=\text{NH})$ bands in complexes **C1** and **C3** shifted to higher frequencies. This shift is associated with the electronic delocalization and may have occurred as a consequence of the coordination through the imine nitrogen and deprotonation of TSCs [45]. On the contrary, the $\nu(\text{N}=\text{NH})$ vibrations in complexes **C2** and **C4** did not shift significantly due to none deprotonation of the TSCs and hence absence of resonance. The presence of the a hydrazinic band $\nu(\text{NN}=\text{H})$ in the region $3180\text{--}3116\text{ cm}^{-1}$ for complexes **C2** and **C4** suggests coordination of the TSC ligands in a neutral manner while its absence in complex **C1** and **C3** suggest deprotonation of the hydrazine nitrogen. The TSC ligands exist in the neutral thione form in the complexes **C2** and **C4** while in complexes **C1** and **C3**, it probably exists as the anionic thiol form. Despite the expected shift to higher frequency on coordination as a neutral ligand and shift to slightly lower frequency on coordination as a thiolate anion [7], the amine bands $\nu(\text{N}=\text{H})$ slightly shifted to lower frequency in the complexes compared to the free ligands. The 2-acetyl-5-methyl TSC Pd(II) complexes, **C1** and **C2** exhibited a shift to lower frequency of the bands associated with thiophene $\nu(\text{C}=\text{S})$ 646 and 536 cm^{-1} respectively



Scheme 1. Synthetic routes for the complexes **C1**, **C2**, **C3** and **C4**.

compared to the free ligand bands observed at 796 and 657 cm^{-1} respectively. This evidence of probable coordination of ligands **L1** and **L2** to the metal via the thiophene sulphur is further supported by the observation of two new Pd–S bands; one for coordination via the thiophene sulphur and the other for coordination via the thioamide sulphur. The spectral studies suggests that the TSC ligand **L1** is coordinated to the palladium metal in a tridentate manner forming a complex of general formula $[\text{Pd}(\text{L})\text{Cl}]$ (Scheme 1) while ligands **L2**, **L3** and **L4** are coordinated in a bidentate manner forming complexes of general formulae $[\text{PdL}_2]$ for complex **C3** and $[\text{PdLCl}_2]$ for complexes **C2** and **C4** (Scheme 1).

3.2.2. ^1H NMR analysis

The ^1H NMR data of the complexes and ligands in $\text{DMSO}-d_6$ are summarized in Table 4. The assignment of the signals in the spectra was based on integrations and assignments previously made for related compounds [7–9]. The ^1H NMR data show that the spectra of complexes **C2** and **C4** contain the proton on nitrogen atom of NN–H group signal observed in the free ligand, further proof that the ligand is coordinated to the central metal in the neutral thione form. On the other hand, the NN–H group proton signal present in NMR spectra of the free ligand is

absent the spectra of complexes **C1** and **C3**, affirming the proposal made from IR data that the ligands **L1** and **L3** exist in the deprotonated form in the complexes (Figs. S2 and S3). The ^1H NMR spectra of complexes showed a downfield shift for the protons of the methyl group attached to the azomethine carbon atom, $(\text{CH}_3)\text{C}=\text{N}$ in complexes **C1** and **C2**, and the azomethine protons $\text{HC}=\text{N}$ on complexes **C3** and **C4** further confirming coordination of the ligand to the metal centers via the azomethine nitrogen. A downfield shift was also observed for the two thiophene ring protons in the complexes **C1** and **C2**, an indication that the ligand may have coordinated to the metal via the thiophene sulphur atom (Table 5).

3.2.3. UV–Vis electronic spectra analysis

The electronic spectra of the ligands and complexes in the ultra violet and visible (UV–Vis) region were obtained in dimethyl sulphoxide (DMSO) solvent. The spectra of the ligands exhibited two intraligand bands in the 252–267 nm and 337–343 nm regions attributed to $\pi-\pi^*$ and $n-\pi^*$ transitions, respectively. The intense bands are generally associated with the $\text{C}=\text{S}$ group, $\text{C}=\text{N}$ group and thiophene ring, which are overlapped in ligands **L1** and **L2** (Fig. S4). Ligands **L3** and **L4** exhibited intense broad band with shoulders in the region 325–359 nm

Table 3

Selected IR vibration frequencies (cm^{-1}) for selected bonds in the ligands and complexes.

Compound	$\nu(\text{C}=\text{N})$	$\nu(\text{C}=\text{S})$	$\nu(\text{N}-\text{N})$	$\nu(\text{C}-\text{S})$ (Thiophene)	$\nu(\text{Pd}-\text{S})$	$\nu(\text{P}-\text{N})$	NN–H	–N–H
Ligand L1	1629, 1521	1286	993	796	–	–	3119	3366, 3263
Complex C1	1624, 1530	–	1046	646	406, 478	551	–	3342, 3271
Ligand L2	1541, 1506	1236	1042	657	–	–	3242	3331
Complex C2	1565, 1514	1229	1048	536	450, 497	530	3181	3272
Ligand L3	1588, 1521	1277	1085	–	–	–	3147	3415, 3254
Complex C3	1583, 1513	–	977	–	475	508	–	3420, 3259
Ligand L4	1532	1256	1084	–	–	–	3164	3353
Complex C4	1607	1164	1018	–	458	501	3041	3246

The IR spectra of the complexes can be found in the [supplementary material file](#) (Fig. S1).

Table 4¹H NMR data (ppm) for the ligands and complexes.

Compound	δ(NNH)	δ(NH ₂)/(NH)	δ(HC=N)	δ(C ₄ H ₂ S) (thiophene)	δ(CH ₃) (thiophene)	δ(CH ₃)-C=N	δ(CH ₃) N(CH ₃)
L1	10.32	7.34	–	7.31, 6.78	2.28	2.42	–
C1	–	8.25	–	7.45, 6.85	2.36	2.45	–
L2	10.25	7.98	–	7.30, 6.72	2.26	2.43	3.02
C2	–	–	–	7.49, 6.87	2.47	2.58	2.90
L3	11.4	8.19, 7.62	7.9	–	–	–	–
C3	–	7.62	8.08	–	–	–	–
L4	11.46	8.30	7.91	–	–	–	2.94
C4	11.10	7.62	8.08	–	–	–	2.83

Table 5

Electronic data for the ligands and Pd(II) complexes.

Compounds	λ_{max} , nm (ϵ , M ⁻¹ cm ⁻¹)			
*L1	341 (1030)			
C1	291 (1589)	342 (1166)	393 (433)	480 (218)
L2		342 (1000)		
C2		340 (1472)	393 (417)	486 (82.7)
**L3			345 (1470)	358sh (11248)
*C3	303 (1770)	362 (1920)	417 (1430)	486 (97)
L4			344 (1487)	361 (1163)
C4	297 (1271)	370 (1690)	388 (1681)	470 (46.2)

Note: 10⁻³M solution of each compound in DMSO was scanned at 200–800 nm range; * 5 × 10⁻⁴ M solution used; **1.5 × 10⁻³M.

associated with the overlap of the –C=C– group of the benzene ring.

These bands associated with the C=S and C=N groups exhibited a red shift of between 20 and 61 nm after coordination of the ligands **L2** and **L4** to the metal center through the imine nitrogen and thiol sulphur respectively. This observation is in agreement with others earlier reported for palladium TSC complexes [9,46]. The spectra of complexes exhibited new strong bands resulting from ligand to metal charge transfer (LMCT) in the region 338–478 nm. These bands may be assigned to S–Pd charge transfer further supporting coordination of the ligand to the metal via the sulphur atom of the C=S group in the neutral thiol form in **C2** and **C4** and anionic form in **C1** and **C3**. The spectra of complexes **C1** and **C2** each had a new band at 483 nm, a further indication that the thiophene sulphur is also involved in coordination as suggested by the FT-IR data. On the contrary, the UV–Vis spectra of complexes **C3** and **C4**, which do not bear the thiophene group, did not show any bands at 483 nm. The Pd(II) ion has d⁸ configuration and is expected to show three bands in the electronic spectrum since palladium complexes have a square planar geometry corresponding to the ¹A_{1g} → ¹A_{2g}, ¹A_{1g} → ¹B_{1g}, and ¹A_{1g} → ¹E_g transitions [8]. The presence of the S and N atoms makes the spectra of Pd(II) complexes complicated since the tails of the S–Pd band may extend up to the visible region of the spectrum thus obscuring the expected d–d transitions. The elemental analysis data obtained for the complexes and the ligands further confirmed the composition and reaction ratio of the ligands and metal ions and hence the proposed molecular structures and coordination modes.

The conductivity measurements of solutions the metal complexes in DMSO indicated that the Pd(II) complexes are non-electrolytes since the values obtained for the compounds were the same as that observed for pure DMSO (Table 6). This clearly shows that the chloride in complexes

Table 6

Conductivity values for the Pd(II) complexes in DMSO.

Metal complexes	[Pd(L1)Cl]	[Pd(L2)Cl ₂]	[Pd(L3) ₂]	[Pd(L4)Cl ₂]	DMSO
Conductivity mS/cm	0.24	0.23	0.24	0.23	0.25

C1, **C2** and **C4** are within the coordination sphere. This is an indication that the complexes are neutral non-electrolytes with coordinated chloride.

The spectroscopic analyses, elemental analysis data and conductivity measurements suggest that the palladium complexes the complexes exhibit coordination modes and structures illustrated in Scheme 1.

It is worth noting that attempts to grow crystals for single crystal X-ray crystallography was not successful.

3.3. Biological studies

3.3.1. Cytotoxicity studies

The cytotoxicity of the ligands and their corresponding Pd(II) complexes were screened against the human cancer (Caco-2, HeLa, HepG2, MCF-7, PC-3) and non-cancer (MCF-12A) cells. The cells were exposed to 100 μM of each compound for 24 h, the cell viability in response to treatments was assessed following MTT assay and expressed as % cell viability. As shown in Fig. 6, the ligands demonstrated varying degrees of toxicity against the test cells. **L1** and **L3** were the most active and exhibited < 40% cell viability in two or three cell lines i.e. PC-3, HepG2 and Caco-2 cells. The PC-3 and HepG2 cells showed higher susceptibility to three (**L1**, **L3** and **L4**) and four ligands, respectively.

The cytotoxic effect of the ligands on the cells was enhanced after coordination to the Pd metal, thus the cytotoxic effects of the Pd(II) complexes were significantly higher than the ligands. Treatment with 100 μM of the Pd(II) complexes resulted in non-selective reduction in proliferation of both cancer and non-cancer cells. In essence, the complexes were more lethal to the cancer cells compared to their respective ligands. A few exceptions where the ligands were more potent than the Pd(II) complexes were observed, for instance, **C3** versus **L3** against Caco-2 (29.4% vs 35.5%) and **C1** versus **L1** against PC-3 (7.7% vs 10%) cells.

The concentration of the compounds that inhibited 50% cell proliferation (IC₅₀) on each cell line was estimated using GraphPad Prism software version 5 (Table 7). The IC₅₀ values revealed that for the ligands to inhibit 50% cell proliferation, IC₅₀ values of more 100 μM was required, with the exception of **L1** and **L2** on HepG2 and MCF-7 cells. **L1** had an IC₅₀ value of 45.3 μM against the human breast cancer cells (MCF-7) and 85 μM on HepG2; and 54 μM for **L2** on HepG2 cells. The Pd(II) complexes were observed to be more active in preventing cell proliferation than the free ligands. Some of the Pd(II) complexes were more potent against specific cell lines with **C2**, **C3** and **C4** exhibiting a broad spectrum potency against all the human cancer cell lines tested. The activity of **C2** against the proliferation of the cells tested increased in the order Caco-2 < HepG2 < MCF-7 < HeLa < PC3. All the Pd (II) complexes (**C1**, **C2**, **C3** and **C4**) exhibited very good activity against the human prostate cancer cell (PC-3) in the order **C3** > **C2** > **C1** > **C4**, with the IC₅₀ values ranging between 2.0 μM (**C3**) and 9.6 μM (**C4**). The IC₅₀ values previously reported for the Pd(II) thiosemicazone complexes against PC-3 cells were much higher (48–58 μM) [4] when compared to the ones reported herein (2.0–9.0 μM). **C2** was an excellent candidate for breast cancer (MCF-7) cells because the




Fig. 6. Effect of the ligands and their Pd (II) complexes against cancer and non-cancer cell lines. The cells were exposed to 100 μ M of L1 vs C1 (A), L2 vs C2 (B), L3 vs C3 (C), and L4 vs C4 (D). * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

concentration needed to inhibit 50% cell proliferation was 7.6 μ M compared to the IC_{50} for the non-cancer breast (MCF-12A) cells. The IC_{50} value for C2 against the MCF-7 cells is comparable to the IC_{50} values (4.41 μ M and 48.0 μ M) reported for Pd complexes on the same cell line [10]. Of all the compounds tested, C2 was the most potent against the cancer cells. The IC_{50} values observed in this study are comparable to those reported for Pd(II) complexed with indole-3-carbaldehyde thiosemicarbazone in literature [47]. It is worth noting, from the data obtained, that the presence or absence of coordinated chloride ion may or may not influence the inhibition of cancer cell proliferation. For instance, C2 and C4 each had two coordinated chloride ions but C2 exhibited higher cytotoxicity mostly on cancer cells while C4 was toxic to all cells (Table 7). The difference in activity between the two complexes can probably be associated with the presence of the two sulphur atoms in C2 and only one sulphur atom in C4.

4. Conclusion

The crystal structures confirm the formation of L2 and L4. The new Pd(II) complexes of 2-acetyl-5-methyl thiophene and CIN thiosemicarbazones were successfully synthesized and their *in vitro* anticancer activities against five human cancer cell lines (colon, cervix,

hepatocellular, breast and prostate) and non-cancer breast cells were determined. The thiosemicarbazone L2, L3 and L4 coordinated to the metal via the nitrogen and sulphur (N,S fashion) of the thiosemicarbazide fragment in a bidentate manner while L1 coordinated to the metal in a tridentate manner via the nitrogen and Sulphur of the thiosemicarbazide fragment, and Sulphur of the thiophene fragment (S,N,S fashion). Conductivity measurements done on the complexes showed that the complexes are non-electrolytes an indication that the chloride ions are within the coordination sphere. This also confirms that the thiosemicarbazones in complexes C1, C2 and C4 are coordinated anions of the thiol tautomer. Except for L1 which gave an IC_{50} value of 45.3 μ M against HepG2 cancer cells, the ligands generally did not show growth inhibition against any of the cells tested at IC_{50} values below 50 μ M. The Pd(II) complexes exhibited excellent growth inhibition against all the human cancer cells tested, which was reduced in the non-cancer breast cells. C3 had an IC_{50} value of 2.0 μ M against the PC-3 cancer cells and can be a suitable candidate for prostate cancer. Further studies are underway to investigate the selectivity of the complexes and their mechanism of action.

Table 7

IC_{50} of ligands and Pd complexes.

Samples	IC_{50} (μ M)					
	Caco-2	MCF-12A	HeLa	PC-3	HepG2	MCF-7
L1	> 100	> 100	> 100	> 100	84.85 $\pm$ 2.01	45.25 $\pm$ 2.57
C1	74.14 $\pm$ 3.16	> 100	> 100	5.53 $\pm$ 0.49	16.26 $\pm$ 1.08	72.65 $\pm$ 1.96
L2	> 100	> 100	> 100	> 100	54.03 $\pm$ 3.54	> 100
C2	15.92 $\pm$ 2.01	> 100	7.92 $\pm$ 0.07	5.3 $\pm$ 0.03	11.68 $\pm$ 2.79	9.53 $\pm$ 2.90
L3	> 100	> 100	> 100	> 100	> 100	> 100
C3	27.87 $\pm$ 0.50	5.15 $\pm$ 0.52	> 100	1.99 $\pm$ 0.21	> 100	10.06 $\pm$ 3.31
L4	> 100	90.6 $\pm$ 5.52	> 100	> 100	> 100	> 100
C4	76.24 $\pm$ 3.15	21.92 $\pm$ 0.05	52.44 $\pm$ 0.63	9.6 $\pm$ 2.32	9.61 $\pm$ 0.58	48.76 $\pm$ 4.55

^aData represents the mean values of three independent experiments.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We would like to thank Jomo Kenyatta University of Agriculture and Technology in Kenya for granting Dr. Eunice Nyawade study leave to undertake this study at the University of the Western Cape, South Africa. We would also like to thank the following research groups: “Organometallics and Nanomaterials” and “DSI/Mintek NIC Biolabels Node” at UWC for allowing us to use their facilities.

Funding

This work was supported by the National Research Foundation, South Africa [grant numbers UD: 116692].

Appendix A. Supplementary data

CCDC2009031 and 2009034 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html> (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033). Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ica.2020.120036>.

References

- [1] D. Kovala-Demertzi, A. Boccarelli, M.A. Demertzis, M. Coluccia, *Chemotherapy* 53 (2007) 148–152.
- [2] X.-Y. Qin, Y.-N. Wang, X.-P. Yang, J.-J. Liang, J.-L. Liu, Z.-H. Luo, *Dalton Trans.* 46 (2017) 16446–16454.
- [3] E. Ramachandran, V. Gandin, R. Bertani, P. Sgarbossa, K. Natarajan, N.S.P. Bhuvanesh, A. Venzo, A. Zoleo, M. Mozzon, A. Dolmella, A. Albinati, C. Castellano, N. Reis Conceição, M.F.C. Guedes da Silva, C. Marzano, *Molecules* 1868 (2020) 25.
- [4] S.N. Mbugua, N.R.S. Sibuyi, L.W. Njenga, R.A. Odhiambo, S.O. Wandiga, M. Meyer, R.A. Lalancette, M.O. Onani, *ACS Omega* 5 (2020) 14942–14954.
- [5] R.M. El-Shazly, G.A.A. Al-Hazmi, S.E. Ghazy, M.S. El-Shahawi, A.A. El-Asmy, *J. Coord. Chem.* 59 (2006) 845–859.
- [6] P. Indrani, B. Falguni, B. Samaresh, *Angew. Chem. Int. Ed.* 40 (2001) 2923–2925.
- [7] T.S. Lobana, R. Sharma, G. Bawa, S. Khanna, *Coord. Chem. Rev.* 253 (2009) 977–1055.
- [8] A.A. Ali, H. Nimir, C. Aktas, V. Huch, U. Rauch, K.-H. Schäfer, M. Veith, *Organometallics* 31 (2012) 2256–2262.
- [9] A. Karakiçuk-İyidoğan, D. Taşdemir, E.E. Oruç-Emre, J. Balzarini, *Eur. J. Med. Chem.* 46 (2011) 5616–5624.
- [10] A.I. Matesanz, I. Leita, P. Souza, *J. Inorg. Biochem.* 125 (2013) 26–31.
- [11] P. Kalaivani, C. Umadevi, R. Prabhakaran, F. Dallemer, P.S. Mohan, K. Natarajan, *Polyhedron* 80 (2014) 97–105.
- [12] N. Bharti, K. Husain, M.T. Gonzalez Garza, D.E. Cruz-Vega, J. Castro-Garza, B.D. Mata-Cardenas, F. Naqvi, A. Azam, *Bioorg. Med. Chem. Lett.* 12 (2002) 3475–3478.
- [13] L. Feun, M. Modiano, K. Lee, J. Mao, A. Marini, N. Savaraj, P. Plezia, B. Almassian, E. Colacino, J. Fischer, S. MacDonald, *Cancer Chemother. Pharmacol.* 50 (2002) 223–229.
- [14] A.G. Quiroga, J.M. Pérez, I. López-Solera, J.R. Masaguer, A. Luque, P. Román, A. Edwards, C. Alonso, C. Navarro-Ranninger, *J. Med. Chem.* 41 (1998) 1399–1408.
- [15] C. Shipman, S.H. Smith, J.C. Drach, D.L. Klayman, *Antiviral Res.* 6 (1986) 197–222.
- [16] D.C. Quenelle, K.A. Keith, E.R. Kern, *Antiviral Res.* 71 (2006) 24–30.
- [17] R.F.F. Costa, A.P. Rebolledo, T. Matencio, H.D.R. Calado, J.D. Ardisson, M.E. Cortés, B.L. Rodrigues, H. Beraldo, *J. Coord. Chem.* 58 (2005) 1307–1319.
- [18] R.K. Agarwal, L. Singh, D.K. Sharma, *Bioinorg. Chem. Appl.* 2006 (2006) 10.
- [19] M. Vieites, L. Otero, D. Santos, J. Toloza, R. Figueroa, E. Norambuena, C. Olea-Azar, G. Aguirre, H. Cerecetto, M. González, A. Morello, J.D. Maya, B. Garat, D. Gambino, *J. Inorg. Biochem.* 102 (2008) 1033–1043.
- [20] M. Vieites, L. Otero, D. Santos, C. Olea-Azar, E. Norambuena, G. Aguirre, H. Cerecetto, M. González, U. Kemmerling, A. Morello, J. Diego Maya, D. Gambino, *J. Inorg. Biochem.* 103 (2009) 411–418.
- [21] R.B. de Oliveira, E.M. de Souza-Fagundes, R.P.P. Soares, A.A. Andrade, A.U. Krettl, C.L. Zani, *Eur. J. Med. Chem.* 43 (2008) 1983–1988.
- [22] P. Yogeeswari, D. Sriram, L.R.J. Sunil Jit, S.S. Kumar, J.P. Stables, *Eur. J. Med. Chem.* 37 (2002) 231–236.
- [23] T. Nitoda, M.D. Fan, I. Kubo, *Phytother. Res.* 22 (2008) 809–813.
- [24] L. Liang-Tzung, T. Chen-Jei, C. Shun-Pang, C. Jin-Liang, W. Shu-Jing, L. Chun-Ching, *Anti-Cancer Agents Med. Chem.* 13 (2013) 1565–1574.
- [25] H. Su-Hyung, I.I. Ahmed, K. Sung-Min, H.D. Cho, K. Byoung-Mog, *Phytother. Res.* 30 (2016) 754–767.
- [26] D.T. Shaughnessy, R.W. Setzer, D.M. DeMarini, *Mutat. Res./Fundam. Mol. Mech. Mutag.* 480–481 (2001) 55–69.
- [27] T. Ohta, K. Watanabe, M. Moriya, Y. Shirasu, T. Kada, *Mutat. Res./Fundam. Mol. Mech. Mutag.* 107 (1983) 219–227.
- [28] C. Bang-Jiao, F. Chun-Sheng, L. Guo-Hui, W. Xiao-Ning, L. Hong-Xiang, R. Dong-Mei, S. Tao, *Mini-Rev. Med. Chem.* 17 (2017) 33–43.
- [29] F. Bisceglie, S. Pinelli, R. Alinovi, M. Goldoni, A. Mutti, A. Camerini, L. Piola, P. Tarasconi, G. Pelosi, *J. Inorg. Biochem.* 140 (2014) 111–125.
- [30] E.A. Nyawade, H.B. Friedrich, B. Omondi, H.Y. Chenia, M. Singh, S. Gorle, *J. Organomet. Chem.* 799–800 (2015) 138–146.
- [31] F.R. Pavan, G.V. Poelhsitz, M.I.F. Barbosa, S.R.A. Leite, A.A. Batista, J. Ellena, L.S. Sato, S.G. Franzblau, V. Moreno, D. Gambino, C.Q.F. Leite, *Eur. J. Med. Chem.* 46 (2011) 5099–5107.
- [32] J. Wiedermann, K. Mereiter, K. Kirchner, *J. Mol. Catal. A: Chem.* 257 (2006) 67–72.
- [33] E.-J. Gao, F. Hong, M.-C. Zhu, C. Ma, S.-K. Liang, J. Zhang, L.-F. Li, L. Wang, Y.-Y. Li, J. Wei, *Eur. J. Med. Chem.* 82 (2014) 172–180.
- [34] Bruker-AXS, Bruker-AXS, Madison, Wisconsin, USA, 2009.
- [35] G.M. Sheldrick, *Acta Crystallogr. A* A64 (2008) 112–122.
- [36] A.L. Spek, *Acta Crystallogr. D* D65 (2009) 148–155.
- [37] K. Brandenburg and H. Putz, *Crystal Impact GbR, Bonn, Germany*, 2005.
- [38] M.A. Ali, S.M.M.-u.-H. Majumder, R.J. Butcher, J.P. Jasinski, J.M. Jasinski, *Polyhedron* 16 (1997) 2749–2754.
- [39] N. Bharti, Shailendra, S. Sharma, F. Naqvi, A. Azam, *Bioorg. Med. Chem.* 11 (2003) 2923–2929.
- [40] I. Antonini, F. Claudi, P. Franchetti, M. Grifantini, S. Martelli, *J. Med. Chem.* 20 (1977) 447–449.
- [41] P.K. Yaman, B. Şen, C.S. Karagöz, E. Subaşı, *J. Organomet. Chem.* 832 (2017) 27–35.
- [42] Z.-L. Jing, M. Yu, X. Chen, *Acta Crystallogr. Section E* 63 (2007) o3714.
- [43] P.A. Gaye, A. Sy, A.D. Sarr, M. Gaye, C. Besnard, *Acta Crystallogr. Section E* 67 (2011) o1168.
- [44] P. Murali Krishna, G.N. Anilkumar, K. Hussain Reddy, M.K. Kokila, *Acta Crystallogr. Section E* 68 (2012) o2842.
- [45] D. Gambino, L. Otero, M. Vieites, M. Boiani, M. González, E.J. Baran, H. Cerecetto, *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.* 68 (2007) 341–348.
- [46] L. Papathanasis, M.A. Demertzis, P.N. Yadav, D. Kovala-Demertzi, C. Prentzas, A. Castiñeiras, S. Skoulia, D.X. West, *Inorg. Chim. Acta* 357 (2004) 4113–4120.
- [47] J. Haribabu, M.M. Tamizh, C. Balachandran, Y. Arun, N.S.P. Bhuvanesh, A. Endo, R. Karvembu, *New J. Chem.* 42 (2018) 10818–10832.